Leimanis M, Karwatsky J, Georges E
Int J Biochem Mol Biol. 2011; 2(1):39-46.
PMID: 21968553
PMC: 3180033.
Bosch I, Croop J
Cytotechnology. 2008; 27(1-3):1-30.
PMID: 19002778
PMC: 3449573.
DOI: 10.1023/A:1008080911522.
Boerner S, Tourne M, Kaufmann S, Bible K
Br J Cancer. 2001; 84(10):1391-6.
PMID: 11355953
PMC: 2363628.
DOI: 10.1054/bjoc.2000.1688.
Dale I, Tuffley W, Callaghan R, Holmes J, Martin K, LUSCOMBE M
Br J Cancer. 1998; 78(7):885-92.
PMID: 9764579
PMC: 2063130.
DOI: 10.1038/bjc.1998.597.
Sha E, Sha M, Kaufmann S
Invest New Drugs. 1996; 13(4):285-94.
PMID: 8824346
DOI: 10.1007/BF00873134.
Constitutive expression of multidrug resistance in human colorectal tumours and cell lines.
Kramer R, Weber T, Morse B, Arceci R, Staniunas R, Steele Jr G
Br J Cancer. 1993; 67(5):959-68.
PMID: 8098614
PMC: 1968473.
DOI: 10.1038/bjc.1993.177.
Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein.
Jette L, Pouliot J, Murphy G, Beliveau R
Biochem J. 1995; 305 ( Pt 3):761-6.
PMID: 7848274
PMC: 1136324.
DOI: 10.1042/bj3050761.
P-glycoprotein structure and evolutionary homologies.
Croop J
Cytotechnology. 1993; 12(1-3):1-32.
PMID: 7765321
Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.
Kramer R, Weber T, Arceci R, Ramchurren N, Kastrinakis W, Steele Jr G
Br J Cancer. 1995; 71(4):670-5.
PMID: 7710927
PMC: 2033717.
DOI: 10.1038/bjc.1995.133.
Electrophoresis of proteins and nucleic acids: I--Theory.
Hayes J, Stockman P
BMJ. 1989; 299(6703):843-6.
PMID: 2510852
PMC: 1837694.
DOI: 10.1136/bmj.299.6703.843.
Structural analysis of the mouse mdr1a (P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multidrug-resistant J774.2 cells.
Hsu S, Cohen D, Kirschner L, Lothstein L, Hartstein M, Horwitz S
Mol Cell Biol. 1990; 10(7):3596-606.
PMID: 1972547
PMC: 360796.
DOI: 10.1128/mcb.10.7.3596-3606.1990.
Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.
Michaeli J, Lebedev Y, Richon V, Chen Z, Marks P, Rifkind R
Mol Cell Biol. 1990; 10(7):3535-40.
PMID: 1972544
PMC: 360788.
DOI: 10.1128/mcb.10.7.3535-3540.1990.
Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.
Richon V, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind R
Proc Natl Acad Sci U S A. 1991; 88(5):1666-70.
PMID: 1672043
PMC: 51085.
DOI: 10.1073/pnas.88.5.1666.
Potentiation of the vincristine effect on P388 mouse leukemia cells by a newly synthesized dihydropyridine analogue, PAK-200.
Shudo N, Fujii R, Matsumoto T, Mizoguchi T, Seto K, Sakoda R
Jpn J Cancer Res. 1992; 83(9):1011-7.
PMID: 1429198
PMC: 5918971.
DOI: 10.1111/j.1349-7006.1992.tb02015.x.
Phosphorylation of elongation factor 2 during Ca(2+)-mediated secretion from rat parotid acini.
Hincke M, Nairn A
Biochem J. 1992; 282 ( Pt 3):877-82.
PMID: 1372803
PMC: 1130869.
DOI: 10.1042/bj2820877.
Functional expression of human mdr1 in the yeast Saccharomyces cerevisiae.
Kuchler K, Thorner J
Proc Natl Acad Sci U S A. 1992; 89(6):2302-6.
PMID: 1347948
PMC: 48645.
DOI: 10.1073/pnas.89.6.2302.